Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Abstract Text:

Yoshikazu Yonemitsu,Yasuji Ueda,Hiroaki Kinoh,Mamoru Hasegawa,Yoshikazu Yonemitsu,Yasuji Ueda,Hiroaki Kinoh,Mamoru Hasegawa,

The utility of recombinant Sendai virus (rSeV) has been considerably examined over the last decade as a potent gene transfer candidate in a cytoplasmic gene expression system. Such risks as excessive immune responses associated with this virus administration in vivo however have limited its applicability in clinical settings as is the case with other viral vectors including adenoviruses. In consequence of extensive assessment on the mechanisms of immune responses against SeV, we found that ex vivo infection of immature dendritic cells (DCs) with SeV demonstrates their spontaneous maturation and activation. We applied this result to create a unique, representative, and powerful agent to activate DCs, namely rSeV-modified DCs (rSeV/DCs), for use in cancer immunotherapy. Use of this system in vivo resulted in the induction of efficient antitumor immunity against vascularized rodent tumors, including melanoma, hepatocellular carcinoma, neuroblastoma, squamous cell carcinoma, and prostatic cancer, and it even frequently associated with elimination of those tumors. These results indicate that rSeV could be a powerful immune booster for DC-based cancer immunotherapy that is worth investigating further. We propose a conceptual term "immunostimulatory virotherapy" to describe this new method of cancer therapy using the rSeV/DCs system.

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Publishing Authors By Initials

Y Yonemitsu,Y Ueda,H Kinoh,M Hasegawa,Y Yonemitsu,Y Ueda,H Kinoh,M Hasegawa,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Journal Published:

PUBLICATION TYPE: Review

Journal: Frontiers in bioscience : a journal and virtual li

VOLUME: 13

Page Numbers: 1892-8

Journal Abbreviation: Front. Biosci.

ISSN: 1093-4715

DAY: 1

MONTH: 01

YEAR: 2008

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Information

Number of References: 19

LANGUAGE: eng

NlmUniqueID: 9709506

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.

AFFILIATION: Graduate School of Medicine, Chiba University,1-8-1 Inohana, Chuo-ku, Chiba, Japan. yonemitu@faculty.chiba-u.jp

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Front Biosci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen Related Publications

• An enhanced self-organizing incremental neural network for online unsupervised learning.
• Body mass index reference values (mean and SD) for Japanese children.
• Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies.
• Central administration of neuromedin U suppresses food intake in chicks.
• Chemokine blockade for lupus model mice.
• Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.
• Distribution of inclusion bodies in tissues from 100 dogs infected with canine distemper virus.
• Effect of MMP/ADAM inhibitors on goblet cell hyperplasia in cultured human bronchial epithelial cells.
• Effect of prostaglandin E2 on recombinant human bone morphogenetic protein-2-stimulated osteoblastic differentiation in human periodontal ligament cells.
• Extraskeletal osteosarcoma of the jaw.
• Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.
• Interferon-gamma inhibits collagen phagocytosis in human fibroblasts by inducing subcortical actin assembly and reducing ability of beta1 integrin to bind to collagen.
• Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.
• Parkinson's Disease Treatment Guidelines 2002 issued by Societas Neurologica Japonica.
• Participation of endogenous IGF-I and TGF-beta 1 with enamel matrix derivative-stimulated cell growth in human periodontal ligament cells.
• Phylogenetic relationships of rodent pinworms (genus Syphacia) in Japan inferred from mitochondrial CO1 gene sequences.
• Possible involvement of organic anion and cation transporters in renal excretion of xanthine derivatives, 3-methylxanthine and enprofylline.
• Production of inhibin A and inhibin B in boars: changes in testicular and circulating levels of dimeric inhibins and characterization of inhibin forms during testis growth.
• Progress in SPECT/CT imaging of prostate cancer.
• Prolonged stress will induce Alzheimer's disease in elderly people by increased release of homocysteic acid.
• Recombinant human bone morphogenetic protein-2 stimulates osteoblast differentiation and suppresses matrix metalloproteinase-1 production in human bone cells isolated from mandibulae.
• Recombinant human bone morphogenetic protein-2 stimulates osteoblastic differentiation in cells isolated from human periodontal ligament.
• Role of neutrophils in acute inflammatory liver injury.
• Sensor fusion for taste sensor and odor sensor.
• Single nucleotide polymorphism genotyping of CYP2C19 using a new automated system.
• Sumoylation, a post-translational regulatory process in plants.
• [Detection of FDG-PET and FDG-PET/CT in head and neck squamous cell carcinoma]
• [Homocysteine metabolism]
• [Non-Q wave myocardial infarction (N-QMI)]
• [Subendocardial infarction]